Christopher E. Nelson

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Assistant Professor

University of Arkansas primary UA Little Rock Arkansas State University

Also affiliated: Dartmouth College (1994–1998); University of North Carolina at Chapel Hill (2024); Rutherford Appleton Laboratory (2020); Oak Ridge National Laboratory (2025); Intel (United States) (2016); North Carolina State University (2024); Lawrence Berkeley National Laboratory (2002–2015); Cooperative Institute for Research in Environmental Sciences (1998); Duke University (2014–2021); Iowa State University (1991); University of Colorado Boulder (1998–2004); Vanderbilt University (2011–2016); Battery Park (1938); Miller Group (Canada) (1952); Center for Nanoscale Science and Technology (2013); Kemin (Belgium) (1993); Capital Meeting Planning (1963); Tashkent Institute of Irrigation and Agricultural Mechanization Engineers (1960); Duke Medical Center (2015–2017); Dow Chemical (United States) (1951–2023); Institute for Soil Sciences (1953); Applied Genetic Technologies (United States) (2019); Nashville Oncology Associates (2014–2015); Northwest Irrigation and Soils Research Laboratory (1953); Genetic Technologies (Australia) (2021); Vanderbilt Health (2015); Hartford Financial Services (United States) (1998); KLA (United States) (1999–2007); Washington State University (1967–1983); Morehouse College (1989); Michigan State University (2002); Atlanta University Center (1989)

Faculty Researcher

38 h-index 145 pubs 5,874 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website Research Group

OverviewAI-generated summary

Christopher E. Nelson's research focuses on gene editing technologies, particularly CRISPR-Cas9, and their application in treating genetic disorders. His work investigates the challenges and optimization strategies for delivering these gene editing tools, with a significant emphasis on Duchenne muscular dystrophy. Nelson has published on preclinical development for exon skipping in Duchenne muscular dystrophy and explored the delivery mechanisms for CRISPR-Cas9 genome editing for this condition.

His research also delves into the immune responses to gene therapy vectors, such as adeno-associated virus (AAV), in preclinical models. Nelson has received federal funding for projects exploring the genomic and cellular factors influencing gene therapy durability and for developing non-viral delivery methods for CRISPR/Cas9. He also contributes to research on extracellular matrix biomaterials and has investigated markers for colorectal tumor progression. With a substantial publication record and high citation count, Nelson leads an active research group at the University of Arkansas at Fayetteville and collaborates with several colleagues within the institution.

Metrics

h-index: 38
Publications: 145
Citations: 5,874

Selected Publications

Targeting mitochondrial dynamics via OPA1 overexpression and BNIP3 knockdown confers protection against pancreatic cancer induced muscle dysfunction (2026)

Physiology DOI OpenAlex
OPTIMIZATION OF PRODUCTION, QUANTIFICATION, AND QUALIFICATION OF LENTIVIRAL VECTORS (2026)

Cytotherapy DOI OpenAlex
Beyond the Cut: Long-read sequencing reveals complex genomic and transcriptomic changes in AAV-CRISPR therapy for Duchenne Muscular Dystrophy (2025)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
Standardizing a Protocol for Streamlined Synthesis and Characterization of Lipid Nanoparticles to Enable Preclinical Research and Education (2025)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
A dual-fluorescence assay for gene delivery vehicle screening in macrophages with an inflammation-inducible reporter construct (2025)

BMC Methods DOI OpenAlex
Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping (2025)

Journal of Neuromuscular Diseases 2 citations DOI OpenAlex
Resistance to Acetyl Coenzyme A Carboxylase (ACCase) Inhibitor in Lolium multiflorum: Effect of Multiple Target-Site Mutations (2024)

Agronomy 3 citations DOI OpenAlex
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci (2024)

Molecular Therapy — Nucleic Acids 2 citations DOI OpenAlex
Optimizing Recombinant Cas9 Expression: Insights from E. coli BL21(DE3) Strains for Enhanced Protein Purification and Genome Editing (2024)

Biomedicines 8 citations DOI OpenAlex
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci (2024)

bioRxiv (Cold Spring Harbor Laboratory) 3 citations DOI OpenAlex
PINE-TREE enables efficient enrichment of prime-edited hPSCs (2023)

Molecular Therapy — Nucleic Acids DOI OpenAlex
Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy (2023)

Biophysics Reviews 14 citations DOI OpenAlex
Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies (2022)

Neoplasia 6 citations DOI OpenAlex
Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies (2022)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
Gene delivery into cells and tissues (2020)

Elsevier eBooks 6 citations DOI OpenAlex